A -- STUDY OF IV MAGNESIUM FOR TREATING ACUTE, SEVERE ASTHMA EXACERBATIONS (MASA)

Notice Date

March 2, 2001

Contracting Office

National Cancer Institute, Research Contracts Branch, ESS, Executive Plaza South, Rm. 620, 6120 Executive Blvd., MSC 7224, Bethesda, MD 20892-7224

ZIP Code

20892-7224

Solicitation Number

N01-AT-11022-64

Point of Contact

James D. Carder, Contract Specialist,(301) 435-3776

E-Mail Address

Click here to contact the Contract Specialist via (carderj@mail.nih.gov)

Description

ELECTRONIC RFP ANNOUNCEMENT-POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY AMENDMENTS. The National Institutes of Health (NIH), The National Center for Complementary and Alternative Medicine seeks a Contractor to conduct a randomized, double blind, placebo-controlled clinical trial to determine the impact of adjuvant intravenous (IV) magnesium sulfate treatment on hospitalization rates and serial spirometric lung function for patients who present to the emergency department (ED) with severe, acute asthma and do not respond to standard therapy. In a randomly selected sample of the population, baseline and post treatment levels of intracellular magnesium should be assessed as they may be a significant determinant of response. The North American Industry Classification System (NAICS) code is 541710. IT IS THE OFFERORS RESPONSIBILITY TO MONITOR THE ABOVE INTERNET SITE FOR THE RELEASE OF THE SOLICITATION AND ANY AMENDMENTS. The solicitation is expected to be issued on or about March 16, 2001. Proposals will be due approximately on April 30, 2001. No collect calls will be accepted.

Web Link

CLICK HERE TO DOWNLOAD A COPY OF THE RPF (http://rcb.nci.nih.gov/appl/rfp/rfps_published.jsp)

Record

Loren Data Corp. 20010306/ASOL003.HTM (W-061 SN50F150)